Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Viridian Therapeutics is expected to report Q3 2026 results on November 4, with analysts projecting a loss of $1.02 per share and revenue of $4.72 million. The company previously reported a $1.05-per-share loss and $0.28 million in revenue.
• VRDN shares opened at $24.09, compared with a 52-week range of $13.18 to $34.29. Analysts maintain a consensus “Moderate Buy” rating and an average price target of $38.92, though one analyst recently downgraded the stock to “strong sell.”
• Viridian is a clinical-stage biotechnology company developing antibody treatments for thyroid eye disease, including intravenous veligrotug and the subcutaneous candidate VRDN-003. An insider recently sold 14,212 shares for approximately $348,000.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) is expected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Viridian Therapeutics to announce earnings of ($1.02) per share and revenue of $4.72 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.02). The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.06 million. On average, analysts expect Viridian Therapeutics to post ($4.07) EPS for the current fiscal year and ($2.43) EPS for the next fiscal year.

Viridian Therapeutics Price Performance

Shares of VRDN stock opened at $24.09 on Wednesday. The firm has a market cap of $2.73 billion, a P/E ratio of -7.15 and a beta of 1.11. Viridian Therapeutics has a 1-year low of $13.18 and a 1-year high of $34.29. The firm's 50-day simple moving average is $21.65 and its 200-day simple moving average is $22.05.

Insider Activity

In related news, insider Jennifer Tousignant sold 14,212 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total value of $348,194.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.40% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on VRDN shares. Wall Street Zen lowered shares of Viridian Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Sunday, October 4th. Weiss Ratings upgraded shares of Viridian Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, September 14th. Royal Bank Of Canada lifted their price target on shares of Viridian Therapeutics from $36.00 to $38.00 and gave the company an "outperform" rating in a report on Tuesday, September 22nd. Wedbush boosted their price objective on shares of Viridian Therapeutics from $32.00 to $43.00 and gave the company an "outperform" rating in a research note on Tuesday, June 30th. Finally, The Goldman Sachs Group restated a "buy" rating and set a $39.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, June 30th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Viridian Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $38.92.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company's lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian's pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.